Dicerna Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Dicerna Pharmaceuticals generated cash of $175,112,000, which is more than the previous year. Cash used in financing activities reached the amount of $59,423,000 last year. Net change in cash is therefore -$24,325,000.
Cash Flow
| 2011 | -8.86M | -501K | 7.25M |
|---|---|---|---|
| 2012 | -15.73M | -120K | -2.96M |
| 2013 | -10.94M | -413K | 54.28M |
| 2014 | -34.76M | -75.76M | 89.99M |
| 2015 | -48.79M | 33.00M | 45.78M |
| 2016 | -48.74M | 13.02M | 534K |
| 2017 | -45.32M | -19.48M | 112.73M |
| 2018 | 18.29M | -202.73M | 169.88M |
| 2019 | -692K | 49.53M | 52.88M |
| 2020 | 175.11M | -258.86M | 59.42M |
DRNA Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 156.71M | 54.98M | 69.53M | 20.86M | 56.05M | 26.06M | 46.59M | 3.67M | 22.49M | 24.60M |
Operating activities | ||||||||||
Net income | -112.74M | -120.45M | -88.85M | -60.04M | -59.51M | -62.83M | -47.93M | -18.51M | -10.12M | -8.55M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.21M | 1.25M | 774K | 778K | 840K | 727K | 848K | 523K | 551K | 474K |
Stock-based compensation expense | 38.91M | 18.82M | 7.88M | 7.77M | 9.16M | 9.73M | 8.23M | 495K | 125K | 173K |
| Deferred income tax benefit | 38.91M | 18.82M | 7.88M | 7.77M | 9.16M | 9.73M | 8.23M | 495K | 125K | 173K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 165.64M | 0 | 0 | 0 | 0 | 0 | 0 | 5.01M | -4.85M | -161K |
Inventories | -482.28M | 0 | 0 | 0 | 0 | 0 | 0 | -8.49M | 0 | 0 |
Accounts payable | 2.20M | 2.06M | -1.21M | 626K | 1.64M | 1.38M | -97K | 116K | -216K | 831K |
Cash generated by operating activities | 175.11M | -692K | 18.29M | -45.32M | -48.74M | -48.79M | -34.76M | -10.94M | -15.73M | -8.86M |
Investing activities | ||||||||||
Purchases Of Investments | -902.12M | -362.12M | -283.37M | -89.71M | -35.03M | -36.12M | -82.62M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -11.74M | -6.34M | -359K | -133K | -449K | -1.13M | -2.01M | -413K | -120K | -501K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -258.86M | 49.53M | -202.73M | -19.48M | 13.02M | 33.00M | -75.76M | -413K | -120K | -501K |
Financing activities | ||||||||||
Common Stock Issued | 39.19M | 45.82M | 168.51M | 43.22M | 0 | 45.43M | 95.02M | 46K | 7K | 70K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -35K | -11K | -27K | -76K | 0 | -5K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -5.02M | -4.14M | -2.97M | -1.37M |
Cash used in financing activities | 59.42M | 52.88M | 169.88M | 112.73M | 534K | 45.78M | 89.99M | 54.28M | -2.96M | 7.25M |
Net Change In Cash | -24.32M | 101.72M | -14.55M | 47.92M | -35.19M | 29.99M | -20.52M | 42.92M | -18.82M | -2.11M |
Cash at end of period | 132.38M | 156.71M | 54.98M | 68.78M | 20.86M | 56.05M | 26.06M | 46.59M | 3.67M | 22.49M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |